FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018590090> ?p ?o ?g. }

• W2018590090 abstract "<h3>Background</h3> Imiquimod is a local immune response modifier that has demonstrated potent antiviral and antitumor activity. It enhances innate and acquired immune responses via endogenous cytokine production and has proven efficacious in clearing superficial basal cell carcinoma (sBCC). <h3>Objective</h3> To evaluate the mechanisms by which topical imiquimod treatment leads to sBCC clearance in vivo. <h3>Design</h3> A pilot, open-label, nonrandomized study. <h3>Setting</h3> Zurich, Switzerland. <h3>Patients</h3> Six persons 18 years or older who had nonrecurrent primary tumors that had not undergone previous biopsy or treatment but were suitable for treatment by surgical excision. The tumors were located on the scalp, extremities, or trunk; had a minimum diameter of 1 cm and a maximum diameter of 2 cm; and were clinically and histologically consistent with sBCC. <h3>Interventions</h3> Daily application of 5% imiquimod cream 5 times per week for a maximum of 6 weeks. When the tumor began to show signs of erosion, it was surgically excised. <h3>Outcome Measures</h3> Parameters reflecting tumor apoptotic status (Bcl-2), expression of death receptors (Fas and Fas ligand [FasL]), intercellular adhesion molecule (ICAM) 1, immunosuppressive microenvironment (interleukin 10), and antigen presentation machinery (transporter associated with antigen presentation [TAP] 1) before and after imiquimod treatment were evaluated. The changes in the interferon γ messenger RNA (mRNA) levels relative to CD4 and CD8 mRNA were assessed using quantitative polymerase chain reaction. <h3>Results</h3> Tumor cells became more susceptible to apoptosis through decreased Bcl-2 expression after treatment with 5% imiquimod cream. Inflammatory infiltrate developed rapidly (within 3 to 5 days after treatment initiation) and was associated with the enhanced expression of ICAM-1. This early response tended to be a mixed cellular response of macrophages and lymphocytes. Interferon γ was produced by CD4 and CD8 T cells. Imiquimod treatment induced a massive increase in macrophage peritumoral and intratumoral infiltration. Interleukin 10 was produced by infiltrating cells but was not produced by tumor cells. Tumor expression of TAP-1 and Fas/FasL appeared to be unaffected in the first 5 days of treatment." @default.
• W2018590090 created "2016-06-24" @default.
• W2018590090 creator A5010117182 @default.
• W2018590090 creator A5042814419 @default.
• W2018590090 creator A5059023559 @default.
• W2018590090 creator A5065899829 @default.
• W2018590090 creator A5088313927 @default.
• W2018590090 creator A5089297467 @default.
• W2018590090 date "2003-10-01" @default.
• W2018590090 modified "2023-09-26" @default.
• W2018590090 title "Mechanisms Underlying Imiquimod-Induced Regression of Basal Cell Carcinoma In Vivo" @default.
• W2018590090 cites W148774612 @default.
• W2018590090 cites W1599260431 @default.
• W2018590090 cites W1861973571 @default.
• W2018590090 cites W1942879517 @default.
• W2018590090 cites W1964060670 @default.
• W2018590090 cites W1969462525 @default.
• W2018590090 cites W1970298612 @default.
• W2018590090 cites W1970758141 @default.
• W2018590090 cites W1972776583 @default.
• W2018590090 cites W1977029773 @default.
• W2018590090 cites W1986031713 @default.
• W2018590090 cites W1996136370 @default.
• W2018590090 cites W2002760446 @default.
• W2018590090 cites W2003280996 @default.
• W2018590090 cites W2009183764 @default.
• W2018590090 cites W2026823187 @default.
• W2018590090 cites W2036971564 @default.
• W2018590090 cites W2038076052 @default.
• W2018590090 cites W2038341079 @default.
• W2018590090 cites W2057257609 @default.
• W2018590090 cites W2069481676 @default.
• W2018590090 cites W2072193086 @default.
• W2018590090 cites W2074127325 @default.
• W2018590090 cites W2075616620 @default.
• W2018590090 cites W2080333440 @default.
• W2018590090 cites W2087792027 @default.
• W2018590090 cites W2113007586 @default.
• W2018590090 cites W2115143367 @default.
• W2018590090 cites W2115301123 @default.
• W2018590090 cites W2115767710 @default.
• W2018590090 cites W2122866085 @default.
• W2018590090 cites W2127327952 @default.
• W2018590090 cites W2130452292 @default.
• W2018590090 cites W2145062884 @default.
• W2018590090 cites W2146418699 @default.
• W2018590090 cites W2149142217 @default.
• W2018590090 cites W2154586728 @default.
• W2018590090 cites W2154851868 @default.
• W2018590090 cites W2157898241 @default.
• W2018590090 cites W2165149100 @default.
• W2018590090 cites W2188523298 @default.
• W2018590090 cites W2314394030 @default.
• W2018590090 cites W2334875839 @default.
• W2018590090 cites W59301961 @default.
• W2018590090 doi "https://doi.org/10.1001/archderm.139.10.1325" @default.
• W2018590090 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14568837" @default.
• W2018590090 hasPublicationYear "2003" @default.
• W2018590090 type Work @default.
• W2018590090 sameAs 2018590090 @default.
• W2018590090 citedByCount "135" @default.
• W2018590090 countsByYear W20185900902012 @default.
• W2018590090 countsByYear W20185900902013 @default.
• W2018590090 countsByYear W20185900902014 @default.
• W2018590090 countsByYear W20185900902015 @default.
• W2018590090 countsByYear W20185900902016 @default.
• W2018590090 countsByYear W20185900902017 @default.
• W2018590090 countsByYear W20185900902018 @default.
• W2018590090 countsByYear W20185900902019 @default.
• W2018590090 countsByYear W20185900902020 @default.
• W2018590090 countsByYear W20185900902021 @default.
• W2018590090 countsByYear W20185900902022 @default.
• W2018590090 countsByYear W20185900902023 @default.
• W2018590090 crossrefType "journal-article" @default.
• W2018590090 hasAuthorship W2018590090A5010117182 @default.
• W2018590090 hasAuthorship W2018590090A5042814419 @default.
• W2018590090 hasAuthorship W2018590090A5059023559 @default.
• W2018590090 hasAuthorship W2018590090A5065899829 @default.
• W2018590090 hasAuthorship W2018590090A5088313927 @default.
• W2018590090 hasAuthorship W2018590090A5089297467 @default.
• W2018590090 hasBestOaLocation W20185900901 @default.
• W2018590090 hasConcept C150903083 @default.
• W2018590090 hasConcept C190283241 @default.
• W2018590090 hasConcept C203014093 @default.
• W2018590090 hasConcept C207001950 @default.
• W2018590090 hasConcept C2779112978 @default.
• W2018590090 hasConcept C31573885 @default.
• W2018590090 hasConcept C502942594 @default.
• W2018590090 hasConcept C55493867 @default.
• W2018590090 hasConcept C66008609 @default.
• W2018590090 hasConcept C71924100 @default.
• W2018590090 hasConcept C86803240 @default.
• W2018590090 hasConcept C8891405 @default.
• W2018590090 hasConceptScore W2018590090C150903083 @default.
• W2018590090 hasConceptScore W2018590090C190283241 @default.
• W2018590090 hasConceptScore W2018590090C203014093 @default.
• W2018590090 hasConceptScore W2018590090C207001950 @default.
• W2018590090 hasConceptScore W2018590090C2779112978 @default.
• W2018590090 hasConceptScore W2018590090C31573885 @default.
• W2018590090 hasConceptScore W2018590090C502942594 @default.

• next